Impel Neuropharma's nose-to-brain drug delivery method sent a small peptide molecule into the brain in a seven-patient trial, the company's chief scientist said. The technology could have applications in central nervous system disorders and pain relief. Angel investors, the NIH, the Pentagon and Washington state's Life Sciences Discovery Fund provided support for the project.
Nose-to-brain drug delivery method works in early trial
SmartBrief Job Listings for Health Care
|Director, Quality Assurance||
|Provider Relations Manager||
Breakthrough Behavioral, Inc.
|Redwood City, CA|
|Director Account Management||
Samaritan Health Services
|Hospital Medical Device Sales||
Linda Hertz Group